Precision oncology: a clinical and patient perspective

Author:

Lassen Ulrik N1ORCID,Makaroff Lydia E23ORCID,Stenzinger Albrecht4,Italiano Antoine5,Vassal Gilles6,Garcia-Foncillas Jesus7,Avouac Bernard8

Affiliation:

1. Rigshospitalet, Copenhagen, 2100, Denmark

2. Fight Bladder Cancer, Oxfordshire, OX39 4DJ, UK

3. World Bladder Cancer Patient Coalition, Brussels, Belgium

4. Institute of Pathology, University Hospital Heidelberg, Heidelberg, 69120, Germany

5. Institut Bergonié, Bordeaux, 33800, France

6. Gustave Roussy Comprehensive Cancer Center, & Unversity Paris-Saclay, Villejuif, 94805, France

7. University Cancer Institute & The Department of Oncology, University Hospital Fundacion Jimenez Diaz, Autonomous University, Madrid, 28033, Spain

8. C2A, Paris, 75012, France

Abstract

Molecular characterization of tumors has shifted cancer treatment strategies away from nonspecific cytotoxic treatment of histology-specific tumors toward targeting of actionable mutations that can be found across multiple cancer types. The development of high-throughput technologies such as next-generation sequencing, combined with decision support applications and availability of patient databases, has provided tools that optimize disease management. Precision oncology has proven success in improving outcomes and quality of life, as well as identifying and overcoming mechanisms of drug resistance and relapse. Addressing challenges that impede its use will improve matching of therapies to patients. Here we review the current status of precision oncology medicine, emphasizing its impact on patients – what they understand about precision oncology medicine and their hopes for the future.

Funder

Bayer

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Reference86 articles.

1. Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining “Actionability” of a Molecular Lesion and Patient Management Support

2. US Food & Drug Administration. Drug approvals and databases. www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases

3. European Medicines Agency. Medicines. www.ema.europa.eu/en/medicines

4. EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients

5. EGFR: The Paradigm of an Oncogene-Driven Lung Cancer

Cited by 22 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3